| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A
|
Shima, Midori
|
|
|
21 |
3 |
p. 534-545
|
artikel
|
| 2 |
Big in Japan: HLA-DRB1∗08:03 and immune thrombotic thrombocytopenic purpura
|
Voorberg, Jan
|
|
|
21 |
3 |
p. 456-459
|
artikel
|
| 3 |
Commentary on “Novel Genetic Regulators of Fibrinogen Synthesis Identified by an In Vitro Experimental Platform”
|
Iwaki, Takayuki
|
|
|
21 |
3 |
p. 463-464
|
artikel
|
| 4 |
Communication from the Scientific Standardization Committees of the International Society on Thrombosis and Haemostasis on vascular endothelium-related biomarkers in disseminated intravascular coagulation
|
Iba, Toshiaki
|
|
|
21 |
3 |
p. 691-699
|
artikel
|
| 5 |
Different inhibitor incidence for individual factor VIII concentrates in 1076 previously untreated patients with severe hemophilia A: data from the PedNet cohort
|
Fischer, Kathelijn
|
|
|
21 |
3 |
p. 700-703
|
artikel
|
| 6 |
Dilemmas in hematology: consults in patients with arterial thrombosis
|
Swan, Dawn
|
|
|
21 |
3 |
p. 421-432
|
artikel
|
| 7 |
DOAC–associated bleeding, hemostatic strategies, and thrombin generation assays - a review of the literature
|
Shaw, Joseph R.
|
|
|
21 |
3 |
p. 433-452
|
artikel
|
| 8 |
Does fetal sex influence the risk of venous thrombosis in pregnancy? A cohort study
|
Virkus, Rie Adser
|
|
|
21 |
3 |
p. 599-605
|
artikel
|
| 9 |
Evaluation and management of oral anticoagulant bleeding: quid didicimus? (what have we learned?)
|
Levy, Jerrold H.
|
|
|
21 |
3 |
p. 460-462
|
artikel
|
| 10 |
Fibrin-glycoprotein VI interaction increases platelet procoagulant activity and impacts clot structure
|
Gauer, Julia S.
|
|
|
21 |
3 |
p. 667-681
|
artikel
|
| 11 |
Fibrin reaches out to GPVI to influence how platelets shape clots
|
Aslan, Joseph E.
|
|
|
21 |
3 |
p. 465-466
|
artikel
|
| 12 |
Hemophilia treatment innovation: 50 years of progress and more to come
|
Mannucci, Pier Mannuccio
|
|
|
21 |
3 |
p. 403-412
|
artikel
|
| 13 |
Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021
|
Abbattista, Maria
|
|
|
21 |
3 |
p. 546-552
|
artikel
|
| 14 |
High prevalence of postpartum hemorrhage in women with rare bleeding disorders in the Netherlands: retrospective data from the RBiN study
|
Maas, Dominique P.M.S.M.
|
|
|
21 |
3 |
p. 499-512
|
artikel
|
| 15 |
Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura
|
Völker, Linus A.
|
|
|
21 |
3 |
p. 559-572
|
artikel
|
| 16 |
In vitro characterization of a novel Arg102 mutation in the ADAMTS13 metalloprotease domain
|
De Waele, Laure
|
|
|
21 |
3 |
p. 682-690
|
artikel
|
| 17 |
Issue Information
|
|
|
|
21 |
3 |
p. e1-e5
|
artikel
|
| 18 |
ISTH News and Updates: Join the ISTH Today
|
|
|
|
21 |
3 |
p. 706-707
|
artikel
|
| 19 |
Modulation of ultralarge immune complexes in heparin–induced thrombocytopenia
|
Cai, Zheng
|
|
|
21 |
3 |
p. 652-666
|
artikel
|
| 20 |
Noninvasive diagnostic work-up for suspected acute pulmonary embolism during pregnancy: a systematic review and meta-analysis of individual patient data
|
Stals, Milou A.M.
|
|
|
21 |
3 |
p. 606-615
|
artikel
|
| 21 |
Novel genetic regulators of fibrinogen synthesis identified by an in vitro experimental platform
|
Dobson, Dre’Von A.
|
|
|
21 |
3 |
p. 522-533
|
artikel
|
| 22 |
Overlapping ADAMTS13 peptide binding profiles of DRB1∗08:03 and DRB1∗11:01 suggest a common etiology of immune-mediated thrombotic thrombocytopenic purpura
|
Sakai, Kazuya
|
|
|
21 |
3 |
p. 616-628
|
artikel
|
| 23 |
Peripheral blood mononuclear cell tissue factor (F3 gene) transcript levels and circulating extracellular vesicles are elevated in severe coronavirus 2019 (COVID-19) disease
|
Girard, Thomas J.
|
|
|
21 |
3 |
p. 629-638
|
artikel
|
| 24 |
Platelet tissue factor pathway inhibitor-α dampens cardiac thrombosis and associated fibrosis in mice
|
Maroney, Susan A.
|
|
|
21 |
3 |
p. 639-651
|
artikel
|
| 25 |
Pre-existing anti-factor VIII immunity alters therapeutic platelet-targeted factor VIII engraftment following busulfan conditioning through cytotoxic CD8 T cells
|
Jing, Weiqing
|
|
|
21 |
3 |
p. 488-498
|
artikel
|
| 26 |
Redefining clinical venous thromboembolism phenotypes: a novel approach using latent class analysis
|
de Winter, Maria A.
|
|
|
21 |
3 |
p. 573-585
|
artikel
|
| 27 |
The effect of a next generation factor VIII mimetic bispecific antibody (Mim8) on assays of factor VIII activity and thrombin generation
|
Bowyer, Annette Elizabeth
|
|
|
21 |
3 |
p. 480-487
|
artikel
|
| 28 |
The ethics of gene therapy for hemophilia: a narrative review
|
Baas, Lieke
|
|
|
21 |
3 |
p. 413-420
|
artikel
|
| 29 |
The mechanistic and structural role of von Willebrand factor in endotoxemia-enhanced deep vein thrombosis in mice
|
Choi, Seon Jae
|
|
|
21 |
3 |
p. 586-598
|
artikel
|
| 30 |
The relative risk of bleeding after medical hospitalization: the medical inpatient thrombosis and hemorrhage study
|
Gergi, Mansour
|
|
|
21 |
3 |
p. 513-521
|
artikel
|
| 31 |
The risk of major bleeding in patients with factor V Leiden or prothrombin G20210A gene mutation while on extended anticoagulant treatment for venous thromboembolism
|
Caiano, Lucia
|
|
|
21 |
3 |
p. 553-558
|
artikel
|
| 32 |
“Thromboinflammation in COVID-19: can α2-macroglobulin help to control the fire?”: Comment from Seitz et al.
|
Seitz, Rainer
|
|
|
21 |
3 |
p. 704-705
|
artikel
|
| 33 |
Tissue factor pathway inhibitor is a potential modifier of bleeding risk in factor XI deficiency
|
Reitsma, Stéphanie E.
|
|
|
21 |
3 |
p. 467-479
|
artikel
|
| 34 |
Von Willebrand factor-inflammation crosstalk in deep vein thrombosis
|
O’Donnell, James S.
|
|
|
21 |
3 |
p. 453-455
|
artikel
|
Tijdschrift beschrijving